Table 3 Vaccine responses by vaccine and CAR-T target in patients (total n = 49) where pre-and post-titers were available for at least one antigen.

From: Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

Vaccine

Overall

CD19

BMCA

Diphtheria (n = 29)

Number of vaccine doses1

3 (1–4)

3 (1–4)

3 (1–3)

Retained immunity2

16 (55%)

15 (75%)

1 (11%)

Responder3

9 (31%)

3 (15%)

6 (67%)

Non-responder4

4 (14%)

2 (10%)

2 (22%)

Haemophilus type B (n = 33)

Number of vaccine doses

3 (1–4)

3 (1–4)

3 (1–3)

Retained immunity

6 (18%)

6 (26%)

0

Responder

16 (49%)

11 (48%)

5 (50%)

Non-responder

11 (33%)

6 (26%)

5 (50%)

Pneumococcus (n = 21)

Number of vaccine doses

3 (1-6)

3 (1–6)

3 (1–3)

Retained immunity

0

0

0

Responder

7 (33%)

5 (38%)

2 (25%)

Non-responder

14 (67%)

8 (62%)

6 (75%)

Tetanus (n = 29)

Number of vaccine doses

3 (1–4)

3 (1–4)

3 (1–3)

Retained immunity

25 (86%)

20 (100%)

5 (56%)

Responder

4 (14%)

0

4 (44%)

Non-responder

0

0

0

Polio 1 and 3 (n = 30)

Number of vaccine doses

3 (1–4)

3 (1–4)

3 (1–3)

Retained immunity

10 (33%)

9 (41%)

1 (12%)

Responder

20 (67%)

13 (59%)

7 (88%)

Non-responder

0

0

0

Varicella (n = 40)

Number of vaccine doses

2 (1–2)

2 (1–2)

2 (1–2)

Retained immunity

27 (68%)

26 (90%)

1 (9%)

Responder

6 (15%)

1 (3%)

5 (45%)

Non-responder

7 (18%)

2 (7%)

5 (45%)

Pertussis (n = 32)

Number of vaccine doses

3 (1–4)

3 (1–4)

3 (1–3)

Retained immunity

8 (25%)

8 (35%)

0

Responder

11 (34%)

8 (35%)

3 (33%)

Non-responder

13 (41%)

7 (30%)

6 (67%)

Hepatitis A (n = 16)

Number of vaccine doses

2 (1–3)

3 (1–3)

2 (1–2)

Retained immunity

9 (56%)

9 (75%)

0

Responder

4 (25%)

2 (17%)

2 (50%)

Non-responder

3 (19%)

1 (8%)

2 (50%)

Hepatitis B (n = 22)

Number of vaccine doses

2 (1–5)

2 (1–5)

2 (1–2)

Retained immunity

6 (27%)

6 (43%)

0

Responder

7 (32%)

3 (21%)

4 (50%)

Non-responder

9 (41%)

5 (36%)

4 (50%)

  1. 1Between the pre- and post-titer, median (min-max), 2Immune both pre- and post- vaccination, 3Non-immune pre-vaccination but immune post vaccination, 4Non-immune both pre- and post-vaccination or lost immunity: immune pre-vaccination but non-immune post-vaccination.
Back to article page